A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
Clinical trial NCT06150157 · RECRUITING
Trial details
- NCT number
- NCT06150157
- Sponsor
- Janssen Research & Development, LLC
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-12-20
- Primary completion
- 2026-12-04
- Enrollment
- 241
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.